Loading
Electromed, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Cunniff James L., was filed 05 Mar 2024.
Electromed, Inc.: what insiders have been doing
Every trade that managers of Electromed, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 20 filings signed by 11 insiders.
No insider bought on the market over the period, while 2 insiders filed 5 sales totalling €369k. The totals exclude 3 filings filed without an amount. Biggest ticket of the year: €364k, sold by Nagel Bradley M. and made public on 8 June 2026 (0.12% of market cap).
Compared with its exchange (5,816 companies, median 19 filings), a count of 20 filings is above the norm. Looking back to 2021, when coverage begins, insiders filed 7 purchases and 11 sales. The 10-K for the year ended 30 June 2026 shows 73.8 m USD of revenue and 11.3 m USD of net income.
Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
76
Thresholds
n/a
Buy Volume
€559,180
7 ops. · all time
Sell Volume
€3M
11 ops. · all time
Who traded when
BuySaleAndrew Summers4 sales
James L. Cunniff3 sales
Bradley M. Nagel2 sales
Kathleen Skarvan1 sale
Since the insiders bought
- +54.4%Entry US$16.00 · Close at T+365 US$24.71
- -18.4%Entry US$11.44 · Close at T+365 US$9.33
- +6.5%Entry US$10.79 · Close at T+365 US$11.49
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 3,526 of 23,476 companies
70.0
score / 100
Value53
Quality87
FCF yld3.7%
Earn yld5.0%
EV/EBITDA15.2x
ROE23%
Gross mgn79%
Net mgn15%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended June 2026 · cache
US$27.48
Analyst consensus
2 analysts1.00/5
US$47.00Target US$48.50(+76%)US$50.00
Income statement
RevenueUS$73.8M
Gross profitUS$57.9M79% margin
EBITDAUS$15M20% margin
Net incomeUS$11.3M15.3% margin
Valuation
PER (trailing)21.3x
P/Book4.3x
Beta0.40
Balance sheet & cash
Market capUS$227.7M
Free Cash FlowUS$8.4M
Debt / Equity0%
Profitability & ownership
ROE23.3%
ROA14.5%
% insiders17.2%
% institutions61.0%
Last declaration on 3 September 2026
Declarations76 total
4,900 shares0Common StockSEC:0001437749-26-029618:0
2,671 shares@ US$27.100.031% mcap11.7% of flowCommon StockSEC:0001437749-26-029617:0
1,102 shares@ US$27.100.013% mcap3.0% of flowCommon StockSEC:0001437749-26-029618:1
9,700 sharesCommon StockSEC:0001437749-26-020030:0
7,003 sharesCommon StockSEC:0001437749-26-020030:1
1,671 sharesCommon StockSEC:0001437749-26-020030:2
1,026 sharesCommon StockSEC:0001437749-26-020030:3
9,700 shares@ US$36.50470.092% mcap57.7% of flowCommonSEC144:0001959173-26-004418
4,334 shares@ US$10.250.012% mcap4.4% of flowCommon StockSEC:0001437749-26-019883:0
5,267 shares@ US$10.710.016% mcap5.6% of flowCommon StockSEC:0001437749-26-019883:1
11,620 shares@ US$36.33550.12% mcap42.1% of flowCommon StockSEC:0001437749-26-019883:2
181 shares@ US$37.1140.0019% mcap0.7% of flowCommon StockSEC:0001437749-26-019883:3
11,801 shares@ US$36.34750.11% mcap42.8% of flowCommonSEC144:0001959173-26-004359
3,000 shares0Common StockSEC:0001437749-25-036837:0
3,000 shares0Common StockSEC:0001437749-25-036834:0
3,000 shares0Common StockSEC:0001437749-25-036833:0
3,000 shares0Common StockSEC:0001437749-25-036832:0
3,000 shares0Common StockSEC:0001437749-25-036831:0
3,000 shares0Common StockSEC:0001437749-25-036829:0
3,000 shares0Common StockSEC:0001437749-25-036828:0
39,378 shares@ US$23.679136.2% of flowCommon StockSEC:0001437749-25-028940:0
1,291 shares@ US$23.955.0% of flowCommon StockSEC:0001437749-25-028374:0
562 shares@ US$23.951.3% of flowCommon StockSEC:0001437749-25-028373:0
15,689 shares@ US$28.7119.6% of flowCommon StockSEC:0001437749-25-004964:0
40,000 shares@ US$1.805.3% of flowCommon StockSEC:0001437749-25-004433:0
25 of 76 declarations
About Electromed, Inc.
Electromed, Inc. (ticker: ELMD) is a U.S.-listed medical device company traded on NYSE American in the United States, with a focused small- to mid-cap profile. Headquartered in New Prague, Minnesota, and founded in 1992, the company has built its business around airway clearance therapy for patients with compromised pulmonary function. Electromed develops, manufactures, markets, and supports products based on High Frequency Chest Wall Oscillation (HFCWO), a therapy designed to help mobilize and clear mucus from the airways. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1488917/000089710124000486/elmd241000_ars.pdf?utm_source=openai))
Its core commercial platform is the SmartVest franchise, including the latest SmartVest Clearway system, the earlier SmartVest SQL, and related garments and accessories. These products are used in conditions such as bronchiectasis, cystic fibrosis, and certain neuromuscular or chronic respiratory disorders. Importantly, Electromed is not just a device vendor: it operates a service-heavy model that includes patient and clinician education, therapy training, follow-up support, reimbursement assistance, and ongoing engagement to help integrate therapy into daily care. That service layer is strategically important in a niche market where reimbursement, adherence, and clinical support heavily influence adoption. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1488917/000143774925034445/elmd20250930_10q.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, Electromed is a specialist rather than a diversified medtech conglomerate. Management consistently frames the company as a leader in the airway clearance category, supported by clinical outcomes data, established reimbursement pathways, and a direct-to-patient/provider go-to-market approach. The business is overwhelmingly U.S.-centric: most revenue is generated domestically, while international sales remain modest. Manufacturing is also based in Minnesota, which suggests a relatively integrated operating model and tighter control over product quality and supply chain execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001488917/000143774926016422/ex_920786.htm?utm_source=openai))
Recent company communications highlight continued growth, profitability, and commercial investment. Management has emphasized salesforce expansion, CRM and capital spending, market-development initiatives, and share repurchases, while investor presentations have continued to position the company as a growing and profitable medical technology business. For investors tracking SEC Form 4 insider activity, ELMD is also notable because insider transactions are followed closely and may reflect compensation-related grants, routine selling, or broader management alignment. Overall, Electromed remains a niche healthcare name with a clear respiratory-care focus, where execution on commercialization, reimbursement, and the expansion of home-based airway clearance demand are the key investment drivers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1488917/000143774925034438/ex_859448.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
